摘要
目的探讨Survivin、尿激酶型纤溶酶原激活剂(uPA)在宫颈癌发生、发展中的作用。方法选择我院手术切除的宫颈癌组织标本47份(肿瘤组)、宫颈上皮内瘤样病变(CIN)标本35份(瘤变组),正常宫颈组织21份(正常组),采用免疫组化SP法检测各组Survivin、uPA的表达,分析两者表达的相关性及与宫颈癌临床病理参数的相关性。结果肿瘤组、瘤变组Survivin、uPA阳性率均明显高于正常组,肿瘤组明显高于瘤变组(P均<0.05);Survivin、uPA阳性表达均与宫颈癌临床分期、组织分化程度、有无淋巴结转移相关,宫颈癌组织中两者表达呈正相关。结论 Survivin、uPA在宫颈癌发生、发展中起重要作用。
Objective To investigate the roles of Survivin and uPA in the occurrence and development of cervical carcinoma. Methods The expression of Survivin and urokinase plasminogen activator (uPA) in 47 cases of cervical carcinoma ( carcinoma group), 35 cases of cervical intraepithelial neoplasia ( CIN, neoplasia group) and 21 cases of normal endometrial tissue (normal group) were detected by immunohistochemistry S-P. The correlation between the two indexes and clinicopathologic parameters of cervical carcinoma. Results The positive expression rates of the Survivin and uPA in carcinoma group and neoplasia group were significantly higher than those in normal group, especially which in the carcinoma group( all P 〈 0.05). Both of their expression were related with lymph nodemetastasis, clinical stage and pathological staging. In cervical carcinoma, the expressions of Survivin and uPA were positively correlated with each other. Conclusion Survivin and uPA play important roles in the occurrence and development of the cervical carcinoma.
出处
《山东医药》
CAS
2012年第35期44-46,共3页
Shandong Medical Journal
基金
邯郸市科学技术研究与发展计划资助项目(1023108103-2)